Viewing Study NCT03836157

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:51 PM
Ignite Modification Date: 2026-02-02 @ 6:17 AM
Study NCT ID: NCT03836157
Status: WITHDRAWN
Last Update Posted: 2019-06-27
First Post: 2019-02-07
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
Sponsor: University of Oklahoma
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Endometrial Cancer View
None Endometrial Adenocarcinoma View
None Endometrial Serous Adenocarcinoma View
None Endometrial Clear Cell Adenocarcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None gynecologic cancer View
None Mirvetuximab soravtansine View